Tipping the GVH/GVL balance by targeting HIF1α.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37992679.
- Also identified by DOI 10.1016/j.xcrm.2023.101295 and PMC identifier 10694739.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Promoting GVL activity while eliminating GVHD is the utmost goal to treat hematological malignancies with allo-HCT. Bailey et al. demonstrate that targeting HIF1α can favor GVL activity while limiting GVHD after allo-HCT even in combination with immune checkpoint inhibition.<sup>1</sup>.
Medical subject headings
- Hematopoietic Stem Cell Transplantation
- Graft vs Host Disease